2,891.20
-37.40
(-1.28%)
As of 2:45:58 PM GMT+5:30. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 4 | 4 |
| Avg. Estimate | 0 | 0 | 52.53 | 59.4 |
| Low Estimate | 0 | 0 | 51.3 | 57.2 |
| High Estimate | 0 | 0 | 53.9 | 62.1 |
| Year Ago EPS | -- | -- | 41.14 | 52.53 |
Revenue Estimate
| Currency in INR | Current Qtr. (Mar 2025) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | -- | 4 | 4 |
| Avg. Estimate | 9.77B | -- | 37.59B | 41.27B |
| Low Estimate | 9.72B | -- | 37.47B | 40.77B |
| High Estimate | 9.81B | -- | 37.74B | 41.59B |
| Year Ago Sales | 9.3B | -- | 34.54B | 37.59B |
| Sales Growth (year/est) | 5.02% | -- | 8.83% | 9.79% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 52.53 | 59.4 |
| 7 Days Ago | 0 | 0 | 50.5 | 57.9 |
| 30 Days Ago | 0 | 0 | 50.5 | 57.9 |
| 60 Days Ago | 0 | 0 | 50.5 | 57.9 |
| 90 Days Ago | 0 | 0 | 50.5 | 57.9 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 4 | 3 |
| Up Last 30 Days | -- | -- | 4 | 3 |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GLAXO.BO | -- | -- | 27.67% | 13.09% |
| S&P 500 | 6.79% | 5.59% | 9.06% | 14.11% |
Related Tickers
BRM.MU Bristol-Myers Squibb Co
43.73
-0.08%
MRK.MX Merck & Co., Inc.
1,560.00
-2.80%
NOTA.BE Novartis AG
97.40
+3.18%
NOV.MU Novo Nordisk A/S
55.89
+0.47%
SNW.HM Sanofi SA
91.01
+1.03%
PFE.CL Pfizer Inc.
95,280.00
-2.60%
4AB.F AbbVie Inc.
151.60
-0.79%
NOTA.DU Novartis AG
96.00
-0.83%
AZNl.XC
BAYZF Bayer Aktiengesellschaft
23.65
0.00%